Related Experiment Video

Updated: Jul 10, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure

Jacob George1, Allan D Struthers

  • 1Ninewells Hospital, Department of Clinical Pharmacology, Level 7, Dundee DD1 9SY, Scotland, UK. j.george@dundee.ac.uk

Expert Opinion on Pharmacotherapy
|November 16, 2007
PubMed

Insights

Aldosterone blockade is key for cardiovascular disease. A new drug, eplerenone, offers an alternative to spironolactone, potentially improving treatment adherence by reducing side effects.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Aldosterone blockade is crucial for managing cardiovascular disease progression.
  • Blocking the rennin-angiotensin-aldosterone system reduces cardiovascular risk.
  • Spironolactone, the long-standing agent, has limiting sexual side effects impacting compliance.

Purpose of the Study:

  • To review the pathophysiology of aldosterone.
  • To critically evaluate the evidence for eplerenone's efficacy.
  • To explore the potential role of eplerenone in cardiovascular therapy.

Main Methods:

  • Literature review of aldosterone pathophysiology.
  • Critical analysis of clinical trial data for eplerenone.
  • Comparison of eplerenone with existing aldosterone blockers.

Main Results:

  • Eplerenone is a selective aldosterone-receptor antagonist.
  • Eplerenone is licensed for heart failure and hypertension.
  • Evidence suggests eplerenone may offer a better side-effect profile than spironolactone.

Conclusions:

  • Eplerenone represents a significant advancement in aldosterone blockade therapy.
  • Selective aldosterone antagonism may improve patient compliance and outcomes.
  • Further research is warranted to fully define eplerenone's role in cardiovascular disease management.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...